You are here

Article Text

Article menu

This article has a Reply. Please see:

other Versions

Download PDFPDF
Correspondence
Detection of myositis-specific antibodies
  1. Jean-Baptiste Vulsteke1,
  2. Ellen De Langhe2,3,
  3. Kristl G Claeys4,5,6,
  4. Doreen Dillaerts7,
  5. Koen Poesen8,9,
  6. Jan Lenaerts2,
  7. René Westhovens2,3,
  8. Philip Van Damme4,10,
  9. Daniel Blockmans1,
  10. Petra De Haes11,
  11. Xavier Bossuyt7,9
  1. 1Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium
  2. 2Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium
  3. 3Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium
  4. 4Department of Neurology, University Hospitals Leuven, Leuven, Belgium
  5. 5Laboratory for Muscle Diseases and Neuropathies, Department of Neurosciences, KU Leuven, Leuven, Belgium
  6. 6Department of Neurology and Institute of Neuropathology, University Hospital RWTH Aachen, Aachen, Germany
  7. 7Department of Microbiology and Immunology, Experimental Laboratory Immunology, KU Leuven, Leuven, Belgium
  8. 8Laboratory for Molecular Neurobiomarker Research, KU Leuven, Leuven, Belgium
  9. 9Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium
  10. 10Department of Neurosciences, Experimental Neurology, VIB Center for Brain & Disease Research, Laboratory of Neurobiology, KU Leuven, Leuven, Belgium
  11. 11Department of Dermatology, University Hospitals Leuven, Leuven, Belgium
  1. Correspondence to Dr Xavier Bossuyt, Laboratory Medicine, University Hospitals Gasthuisberg, Leuven 3000, Belgium; xavier.bossuyt{at}uzleuven.be

http://dx.doi.org/10.1136/annrheumdis-2017-212915

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    It was with much interest that we read the recent European League Against Rheumatism/American College of Rheumatology classification criteria for idiopathic inflammatory myopathies.1 These criteria include Jo-1 autoantibodies, and the authors discussed that future updates of the criteria should also include the more recently identified myositis-specific autoantibodies.1 2 The interest in autoantibodies for classification is also illustrated by a recent proposal for a new clinicoserological classification of adult autoimmune myositis, which is based on the association of autoantibodies with distinct clinical phenotypes.3 4 For example, antibodies to synthetases (eg, Jo-1, PL-7 and PL-12) define the antisynthetase syndrome, anti-MDA-5 antibodies are associated with myositis with overlap features such as interstitial lung disease, anti-TIF-1γ and anti-NXP-2 define a subgroup of dermatomyositis and anti-SRP and anti-HMGCR are associated with necrotising autoimmune myositis.2

    As autoantibodies play a role in the newly proposed classifications,1 …

    View Full Text

    Footnotes

    • J-BV and EDL contributed equally.

    • Contributors EDL, J-BV, KGC, KP and XB designed the study. J-BV, DD, EDL and XB analysed the data. DD performed the autoantibody assays. EDL, KGC, PDH, JL, PVD, RW and DB take care of the patients included in the study and revised the manuscript. J-BV, EDL and XB drafted the manuscript.

    • Funding This study was funded by Alphadia, D-tek, Trinity – Immco and Euroimmun.

    • Competing interests None declared.

    • Patient consent Retrospective study using leftover samples.

    • Ethics approval Local Ethics Committee.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles